異常インスリン症の英語

ストレス関連小胞体タンパク質ＳＥＲＰ１遺伝子機能が染色体上で欠損した、インスリン分泌異常及び／又は小胞体機能異常に起因する２型糖尿病、及び／又は、下垂体での成長ホルモンの生合成異常に起因する下垂体性小人症を発症するモデル非ヒト動物を作製する。例文帳に追加

This model non-human animal having defective stress-associated endoplasmic reticulum protein SERP1 gene function on its chromosome and contracting the type 2 diabetes mellitus caused by insulin secretion abnormality and/or endoplasmic reticulum function abnormality, and/or pituitary dwarfism caused by the abnormal biosynthesis of growth hormone in the pituitary is produced. - 特許庁

肥満症および肥満によって誘発される高脂血症、脂肪肝ならびにインスリン抵抗性に基づくと考えられる耐糖能異常、糖尿病、糖尿病性合併症（糖尿病性末梢神経障害、糖尿病性腎症、糖尿病性網膜症、糖尿病性大血管症など）、高血圧および動脈硬化症の治療に有効なACC活性阻害阻害剤を提供すること。例文帳に追加

To provide an ACC activity inhibitor which is effective for treating obesity, hyperlipemia induced by obesity, abnormal glucose tolerance thought to be based on fatty liver and insulin resistance, diabetes, diabetic complications (diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy and the like), hypertension, and arteriosclerosis. - 特許庁

肥満症および肥満によって誘発される高脂血症、脂肪肝ならびにインスリン抵抗性に基づくと考えられる耐糖能異常、糖尿病、糖尿病性合併症（糖尿病性末梢神経障害、糖尿病性腎症、糖尿病性網膜症、糖尿病性大血管症）、高血圧および動脈硬化症の治療に有効な化合物及び該化合物を含有する医薬組成物を提供すること。例文帳に追加

To obtain a compound effective for treatment of obesity, hyperlipemia and fatty liver induced by obesity, abnormality of glucose tolerance presumed to be based on insulin resistance, diabetes mellitus, diabetic complications (diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy and diabetic great vessel disorder), hypertension and arteriosclerosis, and a medicinal composition containing the compound. - 特許庁

肥満症および肥満によって誘発される高脂血症、脂肪肝ならびにインスリン抵抗性に基づくと考えられる耐糖能異常、糖尿病、糖尿病性合併症（糖尿病性末梢神経障害、糖尿病性腎症、糖尿病性網膜症、糖尿病性大血管症）、高血圧および動脈硬化症の治療に有効なACC活性阻害剤またはそれを用いた治療法の提供すること。例文帳に追加

To provide an ACC activity inhibitor which is effective for treating hyperlipemia induced by obesity and fatness, impaired glucose tolerance estimated to be based on fatty liver and insulin resistance, diabetes, diabetic complication (diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic great vessel disease), hypertension, and arteriosclerosis, and to provide a therapeutic method using the same. - 特許庁

肥満予防・改善、体脂肪燃焼促進、脂肪酸代謝活性化、インスリン抵抗性予防・改善、糖尿病予防・改善、脂質異常症予防・改善、脂肪肝予防・改善、動脈硬化予防・改善、持久力向上、心肥大予防・改善、虚血性心疾患予防・改善に有効なペルオキシソーム増殖剤活性化受容体（ＰＰＡＲ）活性化剤の提供。例文帳に追加

To provide a peroxisomal proliferator-activated receptor (PPAR)-activating agent which is effective for preventing and improving obesity, promoting the combustion of body fats, activating the metabolism of fatty acids, preventing and improving insulin resistance, preventing and improving diabetes, preventing and improving dyslipidemia, preventing and improving fatty liver, preventing and improving arteriosclerosis, improving endurance, preventing and improving cardiomegaly, and preventing and improving ischemic heart diseases. - 特許庁

被験者への糖負荷前および糖負荷一定時間後に尿中に排泄されるミオイノシトールの量を本試薬にて測定し、前後のミオイノシトールの増加量、または増加率をあらかじめ健常者にて設定した特徴的な値と比較して軽症耐糖能異常および／またはインスリン初期分泌不良を検出する。例文帳に追加

The mild impaired glucose tolerance and/or insulin hyposecretion at the early stage are detected by quantifying myoinositol secreted into the urine before loading glucose and after loading glucose to a subject for a definite period of time with the use of a reagent and comparing the increase or the increase ratio in the myoinositol content thus measured with a characteristic level which has been preliminary determined in normal subjects. - 特許庁